ReviewJHEP reports : innovation in hepatology2023
Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022.
Review in JHEP reports : innovation in hepatology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 31 citations in OpenAlex.
- Seroprevalence and Molecular Epidemiology of Hepatitis B and D Viruses in Mauritania: a Systematic Review and Meta-Analysis.Journal of epidemiology and global health · 2026Pooled it
- Prevalence, Risk Factors, and Clinical Profiles of Hepatitis D Virus in Nigeria: A Systematic Review, 2009-2024.Viruses · 2024Pooled it
- Safety and efficacy of libevitug in patients with chronic hepatitis B and D virus coinfection: A single-center, open-label, phase IIa trial in China.Hepatology communications · 2026Trial
- Absence of Detectable Anti-HDV Antibodies Among HBsAg-Positive Blood Donors, HIV-Infected Individuals and Patients With Chronic Hepatitis B in Sao Paulo, Brazil: Evaluation Using a Rapid Lateral Flow Assay.Journal of viral hepatitis · 2026Article
- FDA approval of hepcludex: a milestone in the treatment of chronic hepatitis delta virus infection.Annals of medicine and surgery (2012) · 2026Article
- An Exploratory Cost-Utility Analysis of Screening and Treating Immigrants in Canada for Hepatitis D.Journal of viral hepatitis · 2026Article
- IL-37 and IL-36 Cytokine Profiles in Chronic Hepatitis Delta During Bulevirtide Therapy.Pathogens (Basel, Switzerland) · 2026Article
- Impact of Double Reflex Testing and Linkage to Treatment on Clinical Outcomes of Chronic Hepatitis Delta Virus Infection in the United States.Journal of viral hepatitis · 2026Article
- Development and External Validation of an Algorithm for Identifying HDV RNA-Positive Patients.Gastro hep advances · 2026Article
- CRISPR-based point-of-care diagnostics for viral hepatitis: from molecular design to clinical implementation.Frontiers in bioengineering and biotechnology · 2026Review
- TIGIT expression on natural killer cell subsets is an early indicator of alleviating liver inflammation following bulevirtide treatment in chronic hepatitis D.Hepatology (Baltimore, Md.) · 2025Article
- Derailing the host machinery to achieve replication: how viroid and viroid-like RNAs successfully copy their genomes in hostile territory.RNA biology · 2025Review
- Evaluation of HDV stability under different biological sample collection and storage conditions: implications for molecular diagnosis.Virology journal · 2025Article
- Multimodal characterization of the responsiveness of eight hepatitis D virus genotype isolates to interferon-alpha treatment.Journal of virology · 2025Article
- Host Immune Response in Chronic Hepatitis Delta: Implications for Pathogenesis and Therapy.Pathogens (Basel, Switzerland) · 2025Review
- Article
- Therapy with murinized tobevibart and elebsiran is efficacious in a liver-chimeric mouse model of HDV infection.JHEP reports : innovation in hepatology · 2025Article
- Hepatitis B and D virus entry.Nature reviews. Microbiology · 2025Review
- Providers' Perspectives of Hepatitis Delta Virus Screening and Recommendations for Improvement: A Qualitative Investigation.Gastro hep advances · 2025Article
- Nanoparticles Based Therapeutic Approaches in Oncogenic Viral Infections: A Review.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chronic infection with hepatitis delta virus (HDV) affects between 12-20 million people worldwide and represents the most severe form of viral hepatitis, leading to accelerated liver disease progression, cirrhosis and its complications, such as end-stage-liver disease and hepatocellular carcinoma. From the discovery of HDV in 1977 by Prof. Mario Rizzetto, knowledge on the HDV life cycle and mechanisms of viral spread has expanded. However, little is still known about the natural history of the disease, host-viral interactions, and the role of the immune system in HDV persistence. Diagnosis of HDV is still challenging due to a lack of standardised assays, while accurate viral load quantification is needed to assess response and endpoints of antiviral treatment. Until recently, interferon has represented the only treatment option in patients with chronic hepatitis delta; however, it is associated with low efficacy and a high burden of side effects. The discovery of the entry inhibitor bulevirtide has represented a breakthrough in HDV treatment, by demonstrating high rates of viral suppression in phase II and III trials, results which have been confirmed in real-world settings and in patients with compensated advanced liver disease. In the meantime, other compounds (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.